Luye Pharma Group Ltd. (LYPHF)

Market Cap	963.47M -4.1%
Revenue (ttm)	901.92M +4.1%
Net Income	88.46M +31.1%
EPS	0.02 +26.7%
Shares Out	n/a
PE Ratio	10.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,900,000
Open	0.2041
Previous Close	n/a
Day's Range	0.2041 - 0.2041
52-Week Range	0.2041 - 0.3950
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,221
• Stock Exchange: OTCMKTS
• Ticker Symbol: LYPHF

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY